{
    "url_original": "https://www.wsj.com/articles/startup-pardes-biosciences-joins-hunt-for-covid-19-pill-11629977400?mod=business_lead_pos11",
    "url": "startup-pardes-biosciences-joins-hunt-for-covid-19-pill-11629977400",
    "title": "Startup Pardes Biosciences Joins Hunt for Covid-19 Pill",
    "sub_head": "Company is competing with drugmakers including Pfizer, Shionogi to create an oral medicine that can be widely used outside the hospital",
    "time": "2021-08-26 07:30:00",
    "body": "Startup Pardes Biosciences Inc. has begun clinical trials of a pill for Covid-19, entering the hunt for an oral medicine that could be widely used to treat and prevent the disease.<br />U.S. regulators have approved the drug remdesivir, made by Gilead Sciences Inc., for hospitalized patients, and monoclonal antibodies taken intravenously have gained emergency-use authorizations to treat patients at high risk for developing severe Covid-19 and to prevent hospitalizations.<br />Carlsbad,..."
}